Evidence map›Paper›PMID 39708242›Full record

ArticleInfection2025

Vertebral osteomyelitis in patients with an underlying malignancy or chronic kidney disease - who is at higher risk for adverse outcome?

Dorothee Jochimsen, Ayla Yagdiran, Charlotte Meyer-Schwickerath, Krishnan Sircar, Nikolaus Kernich, Peer Eysel, Carolyn Weber, Norma Jung

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dorothee JochimsenDepartment I of Internal Medicine, Division of Infectious Diseases, University of Cologne, Cologne, Germany. dorothee.jochimsen@uk-koeln.de.
Ayla YagdiranDepartment of Orthopedics and Trauma Surgery, University of Cologne, Cologne, Germany.
Charlotte Meyer-SchwickerathDepartment I of Internal Medicine, Division of Infectious Diseases, University of Cologne, Cologne, Germany.
Krishnan SircarDepartment of Orthopedics and Trauma Surgery, University of Cologne, Cologne, Germany.
Nikolaus KernichDepartment of Orthopedics and Trauma Surgery, University of Cologne, Cologne, Germany.
Peer EyselDepartment of Orthopedics and Trauma Surgery, University of Cologne, Cologne, Germany.
Carolyn WeberDepartment of Cardiothoracic Surgery, University of Cologne, Cologne, Germany.
Norma JungDepartment I of Internal Medicine, Division of Infectious Diseases, University of Cologne, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePatients with vertebral osteomyelitis (VO) and comorbidities, notably chronic kidney disease (CKD), are at risk of early mortality. The aim of this study was to compare characteristics and outcomes of VO patients with an underlying malignancy (ONCO) to VO patients with CKD and VO patients without comorbidities (CONTROL).

methodsWe performed a retrospective analysis of data which was prospectively collected between 2008 and 2020. Primary outcome was treatment failure defined as death and/or recurrence of VO within one year.

results241 VO patients (ONCO = 56; CKD = 47; CONTROL = 138) were analysed. Treatment failure occurred in 26% of ONCO and 45% of CKD patients. Staphylococcus aureus was the most common causative pathogen in the CKD (57%) and CONTROL group (43%). ONCO patients showed a broader distribution of common VO-causing pathogens, with coagulase-negative staphylococci (CoNS) accounting for the highest proportion of causative bacteria (27%). Nevertheless, S.aureus was associated with a significantly higher risk of treatment failure in VO ONCO patients.

conclusionTreatment failure in VO CKD patients was twice as high as in VO ONCO patients. However, both groups showed high treatment failure rates. CoNS should be considered when starting empirical antibiotic treatment in VO ONCO patients. Moreover, oncological patients with VO caused by S.aureus should be monitored closely.

Indexed as

NeoplasmsOsteomyelitisRenal Insufficiency, ChronicSpinal DiseasesAdultAgedAged, 80 and overAnti-Bacterial AgentsFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsTreatment FailureAnti-Bacterial Agents1-year-mortalityChronic kidney diseaseCoagulase-negative staphylococciCoNSMalignancyMalignant diseaseRecurrenceS.aureusSpondylodiscitisStaphylococcus aureusTreatment failureVertebral osteomyelitis

Identifiers

PMID39708242
PMCPMC12316775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.